<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133817</url>
  </required_header>
  <id_info>
    <org_study_id>Yi Chen-2021-5</org_study_id>
    <nct_id>NCT05133817</nct_id>
  </id_info>
  <brief_title>Prophylactic Norepinephrine Infusion Combined With Colloid Coloading for Postspinal Anesthesia Hypotension</brief_title>
  <official_title>Prophylactic Norepinephrine Infusion Combined With 6% Hydroxyethyl Starch (130/0.4) Coload for Postspinal Anesthesia Hypotension in Patients Undergoing Cesarean Section: A Randomized, Controlled, Dose-finding Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the suitable infusion dose of prophylactic&#xD;
      norepinephrine infusion combined with 6% Hydroxyethyl starch (130/0.4) coload for post-spinal&#xD;
      anesthesia hypotension in patients undergoing cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for&#xD;
      cesarean section. The incidence of post-spinal anesthesia hypotension is as high as&#xD;
      62.1-89.7% if prophylactic measures are not taken. Vasopressor has been highly recommended&#xD;
      for routine prevention and/or treatment of post-spinal anesthesia hypotension. As a potential&#xD;
      substitute drug for phenylephrine, norepinephrine has gradually been used in parturients&#xD;
      undergoing cesarean section. There's some evidence that prophylactic infusion of&#xD;
      norepinephrine could effectively reduce the incidence of post-spinal anesthesia hypotension&#xD;
      in parturients undergoing cesarean section. But the ideal infusion dose of norepinephrine&#xD;
      with colloid coload is still unknown. The purpose of this study is to investigate the&#xD;
      suitable infusion dose of prophylactic norepinephrine infusion combined with 6% Hydroxyethyl&#xD;
      starch (130/0.4) coload for post-spinal anesthesia hypotension in patients undergoing&#xD;
      cesarean section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of post-spinal anesthesia hypotension</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 80% of the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall stability of systolic blood pressure control versus baseline</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Evaluated by performance error (PE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe post-spinal anesthesia hypotension.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 60% of the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of nausea and vomiting.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Presence of nausea and vomiting in patients after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of bradycardia.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Heart rate &lt; 55 beats/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hypertension.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &gt;120% of the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH value</measure>
    <time_frame>Immediately after fetal delivery</time_frame>
    <description>Analyse from umbilical arterial blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of oxygen</measure>
    <time_frame>Immediately after fetal delivery</time_frame>
    <description>Analyse from umbilical arterial blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of base excess</measure>
    <time_frame>Immediately after fetal delivery</time_frame>
    <description>Analyse from umbilical arterial blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score (0-10; a higher score means a better outcome)</measure>
    <time_frame>5 min after fetal delivery</time_frame>
    <description>A= Appearance (0-2); P=Pulse (0-2); G=Grimace (0-2); A=Attitude (0-2); R=Respiration (0-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score (0-10;a higher score means a better outcome)</measure>
    <time_frame>5 min after fetal delivery</time_frame>
    <description>A= Appearance (0-2); P=Pulse (0-2); G=Grimace (0-2); A=Attitude (0-2); R=Respiration (0-2)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Adverse Event</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.025 μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.025 μg/kg/min) by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.05 μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.05 μg/kg/min) by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.075 μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.075 μg/kg/min) by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.1μg/kg/min) by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine (0.025 μg/kg/min)</intervention_name>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.</description>
    <arm_group_label>0.025 μg/kg/min group</arm_group_label>
    <other_name>Vasopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine (0.05 μg/kg/min)</intervention_name>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.</description>
    <arm_group_label>0.05 μg/kg/min group</arm_group_label>
    <other_name>Vasopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine (0.075 μg/kg/min)</intervention_name>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.</description>
    <arm_group_label>0.075 μg/kg/min group</arm_group_label>
    <other_name>Vasopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine (0.1 μg/kg/min)</intervention_name>
    <description>Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.</description>
    <arm_group_label>0.1μg/kg/min group</arm_group_label>
    <other_name>Vasopressor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria: Inclusion Criteria:&#xD;
&#xD;
          -  18-40 years&#xD;
&#xD;
          -  Primipara or multipara&#xD;
&#xD;
          -  Singleton pregnancy ≥ 37 weeks&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status classification I to II&#xD;
&#xD;
          -  Scheduled for elective cesarean section under spinal anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body height &lt; 150 cm&#xD;
&#xD;
          -  Body weight &gt; 100 kg or body mass index (BMI) ≥ 40 kg/m2&#xD;
&#xD;
          -  Eclampsia or chronic hypertension or baseline blood pressure ≥ 160mmHg&#xD;
&#xD;
          -  Hemoglobin &lt; 7g/dl&#xD;
&#xD;
          -  Coagulation or renal function disorders&#xD;
&#xD;
          -  Known allergy to hydroxyethyl starch&#xD;
&#xD;
          -  Fetal distress, or known fetal developmental anomaly&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinli Ni, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinli Ni, Dr.</last_name>
    <phone>86-951-674-3252</phone>
    <email>xinlini6@nyfy.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Chen, M.D.</last_name>
    <phone>86-951-674-3252</phone>
    <email>czzyxgp@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>75004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinli Ni, Dr.</last_name>
      <email>xinlini6@nyfy.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chen, M.D.</last_name>
      <email>czzyxgp@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norepinephrine</keyword>
  <keyword>Hydroxyethyl starch</keyword>
  <keyword>Postspinal anesthesia hypotension</keyword>
  <keyword>Coload</keyword>
  <keyword>Cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

